中国飞鹤(06186)发布公告，于2025年12月10日斥资2293.91万港元回购547万股。 ...

（原标题：中国飞鹤(06186)12月10日斥资2293.91万港元回购547万股） 智通财经APP讯，中国飞鹤(06186)发布公告，于2025年12月10日斥资2293.91万港元回购547万股。 ...

Core Viewpoint - Feihe and JD.com have launched two groundbreaking products, Jicui and Qicui, marking a significant innovation in the infant nutrition sector, aimed at meeting the nutritional needs of Chinese babies and leading the industry into a new era of "breast milk-like formula + fresh active technology" [1][3]. Group 1: Product Innovation - The new products focus on "fresh active nutrition," addressing consumer demands for effective nutrient absorption, with 78% of educated mothers prioritizing "active nutrition" and "good absorption" when choosing infant formula [3]. - Feihe's innovation includes the first-ever integration of "fresh raw materials" into the freshness standards of infant formula, creating a closed-loop system from fresh sources to self-produced active ingredients [3][6]. - The Jicui and Qicui formulas utilize a unique low-temperature extraction process from high-quality fresh milk, achieving a freshness increase of at least 23 times and a 6.4 times improvement in nutrient absorption [6][11]. Group 2: Research and Development - Feihe has established one of China's largest breast milk databases and leads national initiatives in breast milk research, contributing to the development of new infant formulas [9][11]. - The formulas emphasize the synergistic effects of nutrients rather than just the quantity of individual nutrients, closely replicating the composition of breast milk [11][14]. - Clinical trials for the new products were conducted under strict standards, ensuring that the results are reliable and closely aligned with breast milk feeding outcomes [15][18]. Group 3: Consumer Engagement and Transparency - Feihe has introduced the industry's first "ingredient-level traceability," allowing consumers to scan QR codes on product packaging to trace the production dates of key ingredients, enhancing transparency in the supply chain [7]. - The company aims to set a new industry benchmark for self-protection formulas, demonstrating significant improvements in immune response and developmental indicators compared to traditional formulas [18]. Group 4: Market Positioning - The launch of Jicui and Qicui represents not just a formula upgrade but a commitment to providing products that are more suitable for Chinese babies, reinforcing Feihe's position as a leader in the infant formula market [18]. - The company plans to continue innovating with products and services that benefit families, ensuring that every baby can thrive under scientifically backed nutrition [18].

| 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06186 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | | 於下列日期開始時的結存(註1) | 2025年12月9日 | | 8,844,115,704 | | 223,136,000 | | | 9,067,251,704 | | 1). 購回股份 (股份被持作庫存股份) | | | -5,470,000 | 0.06185 % | 5,470,000 HK ...

Core Viewpoint - Feihe has launched two innovative products, Jicui and Qicui, in collaboration with JD.com, marking a significant advancement in infant nutrition tailored for Chinese babies, leading the industry into a new era of "breast milk-like formula + fresh active technology" [1][4]. Group 1: Product Innovation - The new products focus on "fresh active nutrition," addressing consumer demands for effective nutrient absorption, with 78% of educated mothers prioritizing "active nutrition" and "good absorption" when selecting infant formula [4]. - Feihe's innovation includes the first-ever integration of "freshness of raw materials" into the standards for infant formula, achieving a closed-loop system from fresh sources to self-produced active ingredients [4][6]. Group 2: Nutritional Advancements - Jicui and Qicui utilize a unique low-temperature extraction process from high-quality fresh milk, resulting in a 23-fold increase in freshness and a 6.4-fold improvement in nutrient absorption [6]. - The products are made from raw materials produced within 30 days, significantly reducing the freshness timeline from years to days, with proprietary extraction techniques enhancing the nutritional quality [6][11]. Group 3: Research and Development - Feihe has established one of China's largest breast milk databases and leads national research initiatives, accumulating significant findings that inform the development of their infant formula [12]. - The company emphasizes a holistic approach to nutrition, focusing on the synergistic effects of nutrients rather than merely increasing individual nutrient levels, effectively replicating the composition of breast milk [14]. Group 4: Clinical Validation - Feihe adheres to a "clinical first, market second" approach, conducting rigorous clinical trials to validate the efficacy of Jicui and Qicui before their market release, ensuring high standards of evidence [21]. - Clinical results indicate that infants fed with Jicui show a 38% reduction in illness rates and a 40% improvement in recovery rates compared to conventional formulas, demonstrating superior immune support [22]. Group 5: Market Positioning - The launch of Jicui and Qicui represents not just a product upgrade but a commitment to providing formulas that are more suitable for Chinese infants, setting a new benchmark in the infant formula industry [22].

证券时报·数据宝统计显示，12月9日有51家香港上市公司进行了股份回购，合计回购5538.65万股，回购 金额12.01亿港元。 腾讯控股回购数量105.60万股，回购金额6.36亿港元，回购最高价为609.500港元，最低价为596.500港 元，年内累计回购金额711.37亿港元；小米集团-W回购数量720.00万股，回购金额2.97亿港元，回购最 高价为41.360港元，最低价为41.080港元，年内累计回购金额44.45亿港元；中远海控回购数量300.00万 股，回购金额4143.27万港元，回购最高价为13.940港元，最低价为13.690港元，年内累计回购金额61.96 亿港元。 以金额进行统计，12月9日回购金额最多的是腾讯控股，回购金额为6.36亿港元；其次是小米集团-W， 回购金额为2.97亿港元；回购金额居前的还有中远海控、中国飞鹤等。回购数量上看，12月9日回购股 数最多的是中国飞鹤，当日回购量为800.70万股；其次是小米集团-W、碧桂园服务等，回购数量分别 为720.00万股、494.70万股。 | 02039 | 中集集团 | 37.50 | 321.79 | 8.710 | 8. ...

| 中远海发(02866) | 100.00 万 | 113.64 万 | 750.50 万 | 0.218% | | --- | --- | --- | --- | --- | | 健康之路(N23031) | 20.00 万 | 94.71 万 | 20.00 万 | 0.023% | | 枫叶教育(01317) | 230.80 万 | 88.74 万 | 8038.00 万 | 2.705% | | 美高梅中国(02282) | 5.25 万 | 87.02 万 | 2993.00 万 | 0.787% | | 联易融科技-W(09959) | 31.00 万 | 72.25 万 | 1.12 亿 | 5.250% | | IGG(00799) | 16.00 万 | 60.16 万 | 1965.30 万 | 1.685% | | 周黑鸭(01458) | 23.50 万 | 37.94 万 | 3022.20 万 | 1.399% | | 叮当健康(09886) | 30.55 万 | 32.58 万 | 306.15 万 | 0.232% | | 朝聚眼科(02219) | 12.00 万 | ...

格隆汇勾股大数据显示，腾讯控股(00700)、小米集团-W(01810)、顺丰控股(06936)、中远海控(01919)、 中国飞鹤(06186)、碧桂园服务(06098)、吉利汽车(00175)、VITASOY INT'L(00345)、中国石油化工股份 (00386)、巨子生物(02367)、固生堂(02273)、锦欣生殖(01951)、粉笔(02469)、瑞声科技(02018)、威高股 份(01066)、同道猎聘(06100)、布鲁可(00325)、明源云(00909)、多点数智(02586)、中集集团(02039)、酷 派集团(02369)、蒙牛乳业(02319)、德康农牧(02419)、昊海生物科技(06826)、中国旭阳集团(01907)、 MONGOL MINING(00975)、名创优品(09896)、绿城服务(02869)、医渡科技(02158)、北森控股 (09669)、信利国际(00732)、永达汽车(03669)、中远海发(02866)、健康之路(02587)、枫叶教育(01317)、 美高梅中国(02282)、联易融科技-W(09959)、IGG(00799)、周黑鸭(01458)、 ...

Core Viewpoint - China Feihe (06186.HK) has been actively repurchasing its shares for 32 consecutive days, with a total expenditure of HKD 940 million, indicating strong confidence in its stock value and market position [1][2]. Group 1: Share Buyback Details - On December 9, 2025, China Feihe repurchased 8.007 million shares at prices ranging from HKD 4.070 to HKD 4.120, totaling HKD 32.93 million [1]. - Since October 24, 2025, the company has repurchased a total of 221 million shares, with an aggregate buyback amount of HKD 940 million, during which the stock price has increased by 2.74% [1][2]. - In 2025, the company has conducted 34 buybacks, acquiring a total of 223 million shares for a total of HKD 950 million [2]. Group 2: Historical Buyback Data - The buyback details include various dates, share quantities, and prices, with the highest buyback price recorded at HKD 4.490 and the lowest at HKD 4.030 [2]. - Notable buyback transactions include: - November 13: 20 million shares at HKD 4.400, totaling HKD 87.86 million [2]. - November 21: 12.3 million shares at HKD 4.200, totaling HKD 51.40 million [2]. - December 8: 7 million shares at HKD 4.130, totaling HKD 28.75 million [2].

中国飞鹤(06186)发布公告，于2025年12月9日，该公司斥资3292.83万港元回购800.7万股股份，每股回 购价格为4.07-4.12港元。 ...